nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ABCB1—ovarian cancer	0.302	1	CbGaD
Propranolol—CYP3A7—Paclitaxel—ovarian cancer	0.0489	0.0991	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0489	0.0991	CbGbCtD
Propranolol—ABCB1—Topotecan—ovarian cancer	0.0483	0.0977	CbGbCtD
Propranolol—CYP3A5—Paclitaxel—ovarian cancer	0.0367	0.0743	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0354	0.0716	CbGbCtD
Propranolol—CYP3A7—Docetaxel—ovarian cancer	0.0354	0.0716	CbGbCtD
Propranolol—ABCB1—Vinorelbine—ovarian cancer	0.034	0.0688	CbGbCtD
Propranolol—CYP2D6—Vinorelbine—ovarian cancer	0.032	0.0649	CbGbCtD
Propranolol—CYP3A4—Topotecan—ovarian cancer	0.0289	0.0585	CbGbCtD
Propranolol—CYP3A5—Docetaxel—ovarian cancer	0.0265	0.0537	CbGbCtD
Propranolol—ABCB1—Paclitaxel—ovarian cancer	0.0239	0.0484	CbGbCtD
Propranolol—CYP3A4—Vinorelbine—ovarian cancer	0.0204	0.0412	CbGbCtD
Propranolol—ABCB1—Docetaxel—ovarian cancer	0.0173	0.035	CbGbCtD
Propranolol—CYP3A4—Paclitaxel—ovarian cancer	0.0143	0.029	CbGbCtD
Propranolol—ABCB1—Doxorubicin—ovarian cancer	0.0129	0.0261	CbGbCtD
Propranolol—CYP2D6—Doxorubicin—ovarian cancer	0.0121	0.0246	CbGbCtD
Propranolol—CYP3A4—Docetaxel—ovarian cancer	0.0104	0.021	CbGbCtD
Propranolol—CYP3A4—Doxorubicin—ovarian cancer	0.00772	0.0156	CbGbCtD
Propranolol—Carvedilol—VEGFA—ovarian cancer	0.000656	0.347	CrCbGaD
Propranolol—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000468	0.00248	CcSEcCtD
Propranolol—Constipation—Topotecan—ovarian cancer	0.000468	0.00248	CcSEcCtD
Propranolol—Pain—Topotecan—ovarian cancer	0.000468	0.00248	CcSEcCtD
Propranolol—Dry eye—Epirubicin—ovarian cancer	0.000466	0.00247	CcSEcCtD
Propranolol—Decreased appetite—Melphalan—ovarian cancer	0.000466	0.00247	CcSEcCtD
Propranolol—Infection—Vinorelbine—ovarian cancer	0.000465	0.00246	CcSEcCtD
Propranolol—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000463	0.00245	CcSEcCtD
Propranolol—Fatigue—Melphalan—ovarian cancer	0.000462	0.00245	CcSEcCtD
Propranolol—Bronchospasm—Docetaxel—ovarian cancer	0.000462	0.00245	CcSEcCtD
Propranolol—Abnormal dreams—Doxorubicin—ovarian cancer	0.000462	0.00245	CcSEcCtD
Propranolol—Nervous system disorder—Vinorelbine—ovarian cancer	0.000459	0.00243	CcSEcCtD
Propranolol—Hyperkalaemia—Doxorubicin—ovarian cancer	0.000459	0.00243	CcSEcCtD
Propranolol—Pain—Melphalan—ovarian cancer	0.000459	0.00243	CcSEcCtD
Propranolol—Skin disorder—Vinorelbine—ovarian cancer	0.000455	0.00241	CcSEcCtD
Propranolol—Hypersensitivity—Chlorambucil—ovarian cancer	0.000453	0.0024	CcSEcCtD
Propranolol—Bradycardia—Paclitaxel—ovarian cancer	0.000452	0.00239	CcSEcCtD
Propranolol—Gastrointestinal pain—Topotecan—ovarian cancer	0.000448	0.00237	CcSEcCtD
Propranolol—Asthenia—Chlorambucil—ovarian cancer	0.000441	0.00234	CcSEcCtD
Propranolol—Pharyngitis—Paclitaxel—ovarian cancer	0.00044	0.00233	CcSEcCtD
Propranolol—Neutropenia—Docetaxel—ovarian cancer	0.000439	0.00233	CcSEcCtD
Propranolol—Urticaria—Topotecan—ovarian cancer	0.000435	0.0023	CcSEcCtD
Propranolol—Body temperature increased—Topotecan—ovarian cancer	0.000433	0.00229	CcSEcCtD
Propranolol—Abdominal pain—Topotecan—ovarian cancer	0.000433	0.00229	CcSEcCtD
Propranolol—Dry eye—Doxorubicin—ovarian cancer	0.000432	0.00229	CcSEcCtD
Propranolol—Visual impairment—Paclitaxel—ovarian cancer	0.000427	0.00226	CcSEcCtD
Propranolol—Urticaria—Melphalan—ovarian cancer	0.000426	0.00226	CcSEcCtD
Propranolol—Diarrhoea—Chlorambucil—ovarian cancer	0.000421	0.00223	CcSEcCtD
Propranolol—Paraesthesia—Vinorelbine—ovarian cancer	0.000421	0.00223	CcSEcCtD
Propranolol—Erythema multiforme—Paclitaxel—ovarian cancer	0.000419	0.00222	CcSEcCtD
Propranolol—Infestation NOS—Docetaxel—ovarian cancer	0.000419	0.00222	CcSEcCtD
Propranolol—Infestation—Docetaxel—ovarian cancer	0.000419	0.00222	CcSEcCtD
Propranolol—Dyspnoea—Vinorelbine—ovarian cancer	0.000418	0.00221	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.000415	0.0022	CcSEcCtD
Propranolol—Cardiac disorder—Paclitaxel—ovarian cancer	0.000412	0.00218	CcSEcCtD
Propranolol—Vascular purpura—Epirubicin—ovarian cancer	0.00041	0.00217	CcSEcCtD
Propranolol—Decreased appetite—Vinorelbine—ovarian cancer	0.000407	0.00216	CcSEcCtD
Propranolol—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000404	0.00214	CcSEcCtD
Propranolol—Cardiac failure congestive—Epirubicin—ovarian cancer	0.000404	0.00214	CcSEcCtD
Propranolol—Fatigue—Vinorelbine—ovarian cancer	0.000404	0.00214	CcSEcCtD
Propranolol—Hypersensitivity—Topotecan—ovarian cancer	0.000403	0.00214	CcSEcCtD
Propranolol—Constipation—Vinorelbine—ovarian cancer	0.000401	0.00212	CcSEcCtD
Propranolol—Pain—Vinorelbine—ovarian cancer	0.000401	0.00212	CcSEcCtD
Propranolol—Hypersensitivity—Melphalan—ovarian cancer	0.000395	0.00209	CcSEcCtD
Propranolol—Asthenia—Topotecan—ovarian cancer	0.000393	0.00208	CcSEcCtD
Propranolol—Alopecia—Paclitaxel—ovarian cancer	0.000392	0.00208	CcSEcCtD
Propranolol—Vomiting—Chlorambucil—ovarian cancer	0.000391	0.00207	CcSEcCtD
Propranolol—Agranulocytosis—Docetaxel—ovarian cancer	0.000391	0.00207	CcSEcCtD
Propranolol—Mental disorder—Paclitaxel—ovarian cancer	0.000389	0.00206	CcSEcCtD
Propranolol—Dermatitis exfoliative—Epirubicin—ovarian cancer	0.000388	0.00206	CcSEcCtD
Propranolol—Erythema—Paclitaxel—ovarian cancer	0.000386	0.00204	CcSEcCtD
Propranolol—Asthenia—Melphalan—ovarian cancer	0.000385	0.00204	CcSEcCtD
Propranolol—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000383	0.00203	CcSEcCtD
Propranolol—Purpura—Epirubicin—ovarian cancer	0.00038	0.00201	CcSEcCtD
Propranolol—Vascular purpura—Doxorubicin—ovarian cancer	0.000379	0.00201	CcSEcCtD
Propranolol—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000379	0.00201	CcSEcCtD
Propranolol—Hypoglycaemia—Epirubicin—ovarian cancer	0.000376	0.00199	CcSEcCtD
Propranolol—Diarrhoea—Topotecan—ovarian cancer	0.000375	0.00198	CcSEcCtD
Propranolol—Lethargy—Epirubicin—ovarian cancer	0.000374	0.00198	CcSEcCtD
Propranolol—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000374	0.00198	CcSEcCtD
Propranolol—Pharyngitis—Docetaxel—ovarian cancer	0.000373	0.00198	CcSEcCtD
Propranolol—Urticaria—Vinorelbine—ovarian cancer	0.000372	0.00197	CcSEcCtD
Propranolol—Abdominal pain—Vinorelbine—ovarian cancer	0.00037	0.00196	CcSEcCtD
Propranolol—Body temperature increased—Vinorelbine—ovarian cancer	0.00037	0.00196	CcSEcCtD
Propranolol—Diarrhoea—Melphalan—ovarian cancer	0.000367	0.00194	CcSEcCtD
Propranolol—Nausea—Chlorambucil—ovarian cancer	0.000365	0.00194	CcSEcCtD
Propranolol—Visual impairment—Docetaxel—ovarian cancer	0.000362	0.00192	CcSEcCtD
Propranolol—Dizziness—Topotecan—ovarian cancer	0.000362	0.00192	CcSEcCtD
Propranolol—Affect lability—Epirubicin—ovarian cancer	0.000361	0.00191	CcSEcCtD
Propranolol—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.000359	0.0019	CcSEcCtD
Propranolol—Erythema multiforme—Docetaxel—ovarian cancer	0.000355	0.00188	CcSEcCtD
Propranolol—Agitation—Paclitaxel—ovarian cancer	0.000355	0.00188	CcSEcCtD
Propranolol—Purpura—Doxorubicin—ovarian cancer	0.000352	0.00186	CcSEcCtD
Propranolol—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.00035	0.00186	CcSEcCtD
Propranolol—Cardiac disorder—Docetaxel—ovarian cancer	0.000349	0.00185	CcSEcCtD
Propranolol—Cardiac arrest—Epirubicin—ovarian cancer	0.000349	0.00185	CcSEcCtD
Propranolol—Vomiting—Topotecan—ovarian cancer	0.000348	0.00184	CcSEcCtD
Propranolol—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000347	0.00184	CcSEcCtD
Propranolol—Mood swings—Epirubicin—ovarian cancer	0.000347	0.00184	CcSEcCtD
Propranolol—Vertigo—Paclitaxel—ovarian cancer	0.000347	0.00184	CcSEcCtD
Propranolol—Lethargy—Doxorubicin—ovarian cancer	0.000346	0.00183	CcSEcCtD
Propranolol—Rash—Topotecan—ovarian cancer	0.000345	0.00183	CcSEcCtD
Propranolol—Hypersensitivity—Vinorelbine—ovarian cancer	0.000345	0.00183	CcSEcCtD
Propranolol—Dermatitis—Topotecan—ovarian cancer	0.000345	0.00183	CcSEcCtD
Propranolol—Vomiting—Melphalan—ovarian cancer	0.000341	0.00181	CcSEcCtD
Propranolol—Rash—Melphalan—ovarian cancer	0.000338	0.00179	CcSEcCtD
Propranolol—Dermatitis—Melphalan—ovarian cancer	0.000338	0.00179	CcSEcCtD
Propranolol—Cough—Paclitaxel—ovarian cancer	0.000337	0.00178	CcSEcCtD
Propranolol—Asthenia—Vinorelbine—ovarian cancer	0.000336	0.00178	CcSEcCtD
Propranolol—Convulsion—Paclitaxel—ovarian cancer	0.000335	0.00177	CcSEcCtD
Propranolol—Affect lability—Doxorubicin—ovarian cancer	0.000334	0.00177	CcSEcCtD
Propranolol—Alopecia—Docetaxel—ovarian cancer	0.000332	0.00176	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.00033	0.00175	CcSEcCtD
Propranolol—Mental disorder—Docetaxel—ovarian cancer	0.000329	0.00174	CcSEcCtD
Propranolol—Erythema—Docetaxel—ovarian cancer	0.000327	0.00173	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000326	0.00173	CcSEcCtD
Propranolol—Atenolol—ABCB1—ovarian cancer	0.000326	0.172	CrCbGaD
Propranolol—Nausea—Topotecan—ovarian cancer	0.000325	0.00172	CcSEcCtD
Propranolol—Cardiac arrest—Doxorubicin—ovarian cancer	0.000322	0.00171	CcSEcCtD
Propranolol—Mood swings—Doxorubicin—ovarian cancer	0.000321	0.0017	CcSEcCtD
Propranolol—Diarrhoea—Vinorelbine—ovarian cancer	0.000321	0.0017	CcSEcCtD
Propranolol—Nausea—Melphalan—ovarian cancer	0.000319	0.00169	CcSEcCtD
Propranolol—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000315	0.00167	CcSEcCtD
Propranolol—Infection—Paclitaxel—ovarian cancer	0.000313	0.00166	CcSEcCtD
Propranolol—Dizziness—Vinorelbine—ovarian cancer	0.00031	0.00164	CcSEcCtD
Propranolol—Nervous system disorder—Paclitaxel—ovarian cancer	0.000309	0.00164	CcSEcCtD
Propranolol—Skin disorder—Paclitaxel—ovarian cancer	0.000306	0.00162	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000305	0.00162	CcSEcCtD
Propranolol—Bronchitis—Epirubicin—ovarian cancer	0.000305	0.00161	CcSEcCtD
Propranolol—Acebutolol—ABCB1—ovarian cancer	0.0003	0.159	CrCbGaD
Propranolol—Vomiting—Vinorelbine—ovarian cancer	0.000298	0.00158	CcSEcCtD
Propranolol—Neutropenia—Epirubicin—ovarian cancer	0.000296	0.00157	CcSEcCtD
Propranolol—Rash—Vinorelbine—ovarian cancer	0.000295	0.00156	CcSEcCtD
Propranolol—Dermatitis—Vinorelbine—ovarian cancer	0.000295	0.00156	CcSEcCtD
Propranolol—Cough—Docetaxel—ovarian cancer	0.000286	0.00151	CcSEcCtD
Propranolol—Insomnia—Paclitaxel—ovarian cancer	0.000285	0.00151	CcSEcCtD
Propranolol—Convulsion—Docetaxel—ovarian cancer	0.000284	0.0015	CcSEcCtD
Propranolol—Paraesthesia—Paclitaxel—ovarian cancer	0.000283	0.0015	CcSEcCtD
Propranolol—Infestation NOS—Epirubicin—ovarian cancer	0.000282	0.0015	CcSEcCtD
Propranolol—Infestation—Epirubicin—ovarian cancer	0.000282	0.0015	CcSEcCtD
Propranolol—Bronchitis—Doxorubicin—ovarian cancer	0.000282	0.00149	CcSEcCtD
Propranolol—Dyspnoea—Paclitaxel—ovarian cancer	0.000281	0.00149	CcSEcCtD
Propranolol—Somnolence—Paclitaxel—ovarian cancer	0.00028	0.00148	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00028	0.00148	CcSEcCtD
Propranolol—Nausea—Vinorelbine—ovarian cancer	0.000278	0.00147	CcSEcCtD
Propranolol—Dyspepsia—Paclitaxel—ovarian cancer	0.000277	0.00147	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000277	0.00147	CcSEcCtD
Propranolol—Neutropenia—Doxorubicin—ovarian cancer	0.000274	0.00145	CcSEcCtD
Propranolol—Decreased appetite—Paclitaxel—ovarian cancer	0.000274	0.00145	CcSEcCtD
Propranolol—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000272	0.00144	CcSEcCtD
Propranolol—Fatigue—Paclitaxel—ovarian cancer	0.000272	0.00144	CcSEcCtD
Propranolol—Constipation—Paclitaxel—ovarian cancer	0.000269	0.00143	CcSEcCtD
Propranolol—Pain—Paclitaxel—ovarian cancer	0.000269	0.00143	CcSEcCtD
Propranolol—Anaphylactic shock—Docetaxel—ovarian cancer	0.000267	0.00141	CcSEcCtD
Propranolol—Infection—Docetaxel—ovarian cancer	0.000265	0.00141	CcSEcCtD
Propranolol—Agranulocytosis—Epirubicin—ovarian cancer	0.000264	0.0014	CcSEcCtD
Propranolol—Nervous system disorder—Docetaxel—ovarian cancer	0.000262	0.00139	CcSEcCtD
Propranolol—Infestation NOS—Doxorubicin—ovarian cancer	0.000261	0.00138	CcSEcCtD
Propranolol—Infestation—Doxorubicin—ovarian cancer	0.000261	0.00138	CcSEcCtD
Propranolol—Skin disorder—Docetaxel—ovarian cancer	0.000259	0.00137	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000259	0.00137	CcSEcCtD
Propranolol—Bradycardia—Epirubicin—ovarian cancer	0.000258	0.00137	CcSEcCtD
Propranolol—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000258	0.00136	CcSEcCtD
Propranolol—Metoprolol—ABCB1—ovarian cancer	0.000254	0.134	CrCbGaD
Propranolol—Pharyngitis—Epirubicin—ovarian cancer	0.000252	0.00133	CcSEcCtD
Propranolol—Urticaria—Paclitaxel—ovarian cancer	0.00025	0.00133	CcSEcCtD
Propranolol—Body temperature increased—Paclitaxel—ovarian cancer	0.000249	0.00132	CcSEcCtD
Propranolol—Abdominal pain—Paclitaxel—ovarian cancer	0.000249	0.00132	CcSEcCtD
Propranolol—Visual impairment—Epirubicin—ovarian cancer	0.000244	0.00129	CcSEcCtD
Propranolol—Agranulocytosis—Doxorubicin—ovarian cancer	0.000244	0.00129	CcSEcCtD
Propranolol—Insomnia—Docetaxel—ovarian cancer	0.000242	0.00128	CcSEcCtD
Propranolol—Paraesthesia—Docetaxel—ovarian cancer	0.00024	0.00127	CcSEcCtD
Propranolol—Erythema multiforme—Epirubicin—ovarian cancer	0.00024	0.00127	CcSEcCtD
Propranolol—Bradycardia—Doxorubicin—ovarian cancer	0.000239	0.00127	CcSEcCtD
Propranolol—Dyspnoea—Docetaxel—ovarian cancer	0.000238	0.00126	CcSEcCtD
Propranolol—Somnolence—Docetaxel—ovarian cancer	0.000237	0.00126	CcSEcCtD
Propranolol—Cardiac disorder—Epirubicin—ovarian cancer	0.000235	0.00125	CcSEcCtD
Propranolol—Dyspepsia—Docetaxel—ovarian cancer	0.000235	0.00125	CcSEcCtD
Propranolol—Pharyngitis—Doxorubicin—ovarian cancer	0.000233	0.00123	CcSEcCtD
Propranolol—Decreased appetite—Docetaxel—ovarian cancer	0.000232	0.00123	CcSEcCtD
Propranolol—Hypersensitivity—Paclitaxel—ovarian cancer	0.000232	0.00123	CcSEcCtD
Propranolol—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000231	0.00122	CcSEcCtD
Propranolol—Fatigue—Docetaxel—ovarian cancer	0.00023	0.00122	CcSEcCtD
Propranolol—Constipation—Docetaxel—ovarian cancer	0.000228	0.00121	CcSEcCtD
Propranolol—Pain—Docetaxel—ovarian cancer	0.000228	0.00121	CcSEcCtD
Propranolol—Visual impairment—Doxorubicin—ovarian cancer	0.000226	0.0012	CcSEcCtD
Propranolol—Asthenia—Paclitaxel—ovarian cancer	0.000226	0.0012	CcSEcCtD
Propranolol—Alopecia—Epirubicin—ovarian cancer	0.000224	0.00119	CcSEcCtD
Propranolol—Mental disorder—Epirubicin—ovarian cancer	0.000222	0.00118	CcSEcCtD
Propranolol—Erythema multiforme—Doxorubicin—ovarian cancer	0.000222	0.00117	CcSEcCtD
Propranolol—Erythema—Epirubicin—ovarian cancer	0.000221	0.00117	CcSEcCtD
Propranolol—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000218	0.00116	CcSEcCtD
Propranolol—Cardiac disorder—Doxorubicin—ovarian cancer	0.000218	0.00115	CcSEcCtD
Propranolol—Diarrhoea—Paclitaxel—ovarian cancer	0.000216	0.00114	CcSEcCtD
Propranolol—Abdominal pain—Docetaxel—ovarian cancer	0.000211	0.00112	CcSEcCtD
Propranolol—Body temperature increased—Docetaxel—ovarian cancer	0.000211	0.00112	CcSEcCtD
Propranolol—Dizziness—Paclitaxel—ovarian cancer	0.000208	0.0011	CcSEcCtD
Propranolol—Alopecia—Doxorubicin—ovarian cancer	0.000207	0.0011	CcSEcCtD
Propranolol—Mental disorder—Doxorubicin—ovarian cancer	0.000206	0.00109	CcSEcCtD
Propranolol—Erythema—Doxorubicin—ovarian cancer	0.000204	0.00108	CcSEcCtD
Propranolol—Agitation—Epirubicin—ovarian cancer	0.000203	0.00107	CcSEcCtD
Propranolol—Vomiting—Paclitaxel—ovarian cancer	0.0002	0.00106	CcSEcCtD
Propranolol—Rash—Paclitaxel—ovarian cancer	0.000199	0.00105	CcSEcCtD
Propranolol—Dermatitis—Paclitaxel—ovarian cancer	0.000198	0.00105	CcSEcCtD
Propranolol—Vertigo—Epirubicin—ovarian cancer	0.000198	0.00105	CcSEcCtD
Propranolol—Hypersensitivity—Docetaxel—ovarian cancer	0.000197	0.00104	CcSEcCtD
Propranolol—Cough—Epirubicin—ovarian cancer	0.000193	0.00102	CcSEcCtD
Propranolol—Asthenia—Docetaxel—ovarian cancer	0.000192	0.00101	CcSEcCtD
Propranolol—Convulsion—Epirubicin—ovarian cancer	0.000191	0.00101	CcSEcCtD
Propranolol—Agitation—Doxorubicin—ovarian cancer	0.000188	0.000994	CcSEcCtD
Propranolol—Nausea—Paclitaxel—ovarian cancer	0.000187	0.000991	CcSEcCtD
Propranolol—Propafenone—ABCB1—ovarian cancer	0.000187	0.0989	CrCbGaD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000187	0.000988	CcSEcCtD
Propranolol—Vertigo—Doxorubicin—ovarian cancer	0.000183	0.000972	CcSEcCtD
Propranolol—Diarrhoea—Docetaxel—ovarian cancer	0.000183	0.000968	CcSEcCtD
Propranolol—Anaphylactic shock—Epirubicin—ovarian cancer	0.00018	0.000954	CcSEcCtD
Propranolol—Infection—Epirubicin—ovarian cancer	0.000179	0.000948	CcSEcCtD
Propranolol—Cough—Doxorubicin—ovarian cancer	0.000178	0.000944	CcSEcCtD
Propranolol—Convulsion—Doxorubicin—ovarian cancer	0.000177	0.000937	CcSEcCtD
Propranolol—Nervous system disorder—Epirubicin—ovarian cancer	0.000177	0.000936	CcSEcCtD
Propranolol—Dizziness—Docetaxel—ovarian cancer	0.000177	0.000935	CcSEcCtD
Propranolol—Skin disorder—Epirubicin—ovarian cancer	0.000175	0.000927	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000173	0.000915	CcSEcCtD
Propranolol—Vomiting—Docetaxel—ovarian cancer	0.00017	0.000899	CcSEcCtD
Propranolol—Rash—Docetaxel—ovarian cancer	0.000168	0.000892	CcSEcCtD
Propranolol—Carvedilol—ABCB1—ovarian cancer	0.000168	0.089	CrCbGaD
Propranolol—Dermatitis—Docetaxel—ovarian cancer	0.000168	0.000891	CcSEcCtD
Propranolol—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000167	0.000883	CcSEcCtD
Propranolol—Infection—Doxorubicin—ovarian cancer	0.000166	0.000877	CcSEcCtD
Propranolol—Nervous system disorder—Doxorubicin—ovarian cancer	0.000163	0.000866	CcSEcCtD
Propranolol—Insomnia—Epirubicin—ovarian cancer	0.000163	0.000863	CcSEcCtD
Propranolol—Skin disorder—Doxorubicin—ovarian cancer	0.000162	0.000858	CcSEcCtD
Propranolol—Paraesthesia—Epirubicin—ovarian cancer	0.000162	0.000857	CcSEcCtD
Propranolol—Dyspnoea—Epirubicin—ovarian cancer	0.000161	0.000851	CcSEcCtD
Propranolol—Somnolence—Epirubicin—ovarian cancer	0.00016	0.000848	CcSEcCtD
Propranolol—Nausea—Docetaxel—ovarian cancer	0.000159	0.00084	CcSEcCtD
Propranolol—Dyspepsia—Epirubicin—ovarian cancer	0.000159	0.00084	CcSEcCtD
Propranolol—Decreased appetite—Epirubicin—ovarian cancer	0.000157	0.000829	CcSEcCtD
Propranolol—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000156	0.000824	CcSEcCtD
Propranolol—Fatigue—Epirubicin—ovarian cancer	0.000155	0.000823	CcSEcCtD
Propranolol—Pain—Epirubicin—ovarian cancer	0.000154	0.000816	CcSEcCtD
Propranolol—Constipation—Epirubicin—ovarian cancer	0.000154	0.000816	CcSEcCtD
Propranolol—Insomnia—Doxorubicin—ovarian cancer	0.000151	0.000798	CcSEcCtD
Propranolol—Paraesthesia—Doxorubicin—ovarian cancer	0.00015	0.000793	CcSEcCtD
Propranolol—Dyspnoea—Doxorubicin—ovarian cancer	0.000149	0.000787	CcSEcCtD
Propranolol—Somnolence—Doxorubicin—ovarian cancer	0.000148	0.000785	CcSEcCtD
Propranolol—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000147	0.00078	CcSEcCtD
Propranolol—Dyspepsia—Doxorubicin—ovarian cancer	0.000147	0.000777	CcSEcCtD
Propranolol—Decreased appetite—Doxorubicin—ovarian cancer	0.000145	0.000767	CcSEcCtD
Propranolol—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000144	0.000762	CcSEcCtD
Propranolol—Fatigue—Doxorubicin—ovarian cancer	0.000144	0.000761	CcSEcCtD
Propranolol—Urticaria—Epirubicin—ovarian cancer	0.000143	0.000758	CcSEcCtD
Propranolol—Constipation—Doxorubicin—ovarian cancer	0.000143	0.000755	CcSEcCtD
Propranolol—Pain—Doxorubicin—ovarian cancer	0.000143	0.000755	CcSEcCtD
Propranolol—Abdominal pain—Epirubicin—ovarian cancer	0.000142	0.000754	CcSEcCtD
Propranolol—Body temperature increased—Epirubicin—ovarian cancer	0.000142	0.000754	CcSEcCtD
Propranolol—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000136	0.000722	CcSEcCtD
Propranolol—Hypersensitivity—Epirubicin—ovarian cancer	0.000133	0.000703	CcSEcCtD
Propranolol—Urticaria—Doxorubicin—ovarian cancer	0.000132	0.000701	CcSEcCtD
Propranolol—Abdominal pain—Doxorubicin—ovarian cancer	0.000132	0.000698	CcSEcCtD
Propranolol—Body temperature increased—Doxorubicin—ovarian cancer	0.000132	0.000698	CcSEcCtD
Propranolol—Asthenia—Epirubicin—ovarian cancer	0.000129	0.000685	CcSEcCtD
Propranolol—Diarrhoea—Epirubicin—ovarian cancer	0.000123	0.000653	CcSEcCtD
Propranolol—Hypersensitivity—Doxorubicin—ovarian cancer	0.000123	0.00065	CcSEcCtD
Propranolol—Asthenia—Doxorubicin—ovarian cancer	0.00012	0.000633	CcSEcCtD
Propranolol—Dizziness—Epirubicin—ovarian cancer	0.000119	0.000631	CcSEcCtD
Propranolol—Vomiting—Epirubicin—ovarian cancer	0.000115	0.000607	CcSEcCtD
Propranolol—Diarrhoea—Doxorubicin—ovarian cancer	0.000114	0.000604	CcSEcCtD
Propranolol—Rash—Epirubicin—ovarian cancer	0.000114	0.000602	CcSEcCtD
Propranolol—Dermatitis—Epirubicin—ovarian cancer	0.000113	0.000601	CcSEcCtD
Propranolol—Dizziness—Doxorubicin—ovarian cancer	0.00011	0.000584	CcSEcCtD
Propranolol—Nausea—Epirubicin—ovarian cancer	0.000107	0.000567	CcSEcCtD
Propranolol—Vomiting—Doxorubicin—ovarian cancer	0.000106	0.000561	CcSEcCtD
Propranolol—Rash—Doxorubicin—ovarian cancer	0.000105	0.000557	CcSEcCtD
Propranolol—Dermatitis—Doxorubicin—ovarian cancer	0.000105	0.000556	CcSEcCtD
Propranolol—Nausea—Doxorubicin—ovarian cancer	9.9e-05	0.000524	CcSEcCtD
Propranolol—CYP2D6—Metabolism—SLC2A1—ovarian cancer	3.29e-06	0.000258	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL6ST—ovarian cancer	3.25e-06	0.000255	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ESR1—ovarian cancer	3.23e-06	0.000254	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—VEGFA—ovarian cancer	3.22e-06	0.000253	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CD—ovarian cancer	3.2e-06	0.000251	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CD—ovarian cancer	3.2e-06	0.000251	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—APC—ovarian cancer	3.19e-06	0.000251	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CG—ovarian cancer	3.19e-06	0.000251	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—NRAS—ovarian cancer	3.19e-06	0.000251	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—STAT3—ovarian cancer	3.19e-06	0.00025	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL6ST—ovarian cancer	3.18e-06	0.00025	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—NRAS—ovarian cancer	3.18e-06	0.00025	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—PIK3CA—ovarian cancer	3.17e-06	0.000249	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP1B1—ovarian cancer	3.15e-06	0.000247	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.13e-06	0.000246	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—APC—ovarian cancer	3.12e-06	0.000245	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CG—ovarian cancer	3.12e-06	0.000245	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—NRAS—ovarian cancer	3.12e-06	0.000245	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—ERBB2—ovarian cancer	3.11e-06	0.000244	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CB—ovarian cancer	3.07e-06	0.000241	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MTOR—ovarian cancer	3.07e-06	0.000241	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—MAPK3—ovarian cancer	3.06e-06	0.00024	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CG—ovarian cancer	3.06e-06	0.00024	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—APC—ovarian cancer	3.06e-06	0.00024	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—NRAS—ovarian cancer	3.06e-06	0.00024	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MAPK3—ovarian cancer	3.04e-06	0.000239	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	3.04e-06	0.000239	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.03e-06	0.000237	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—MAPK3—ovarian cancer	2.99e-06	0.000235	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PPP2R1A—ovarian cancer	2.97e-06	0.000233	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MYC—ovarian cancer	2.96e-06	0.000232	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CXCL8—ovarian cancer	2.95e-06	0.000232	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—HRAS—ovarian cancer	2.93e-06	0.00023	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—FASN—ovarian cancer	2.93e-06	0.00023	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—MAPK3—ovarian cancer	2.93e-06	0.00023	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—MAPK1—ovarian cancer	2.91e-06	0.000229	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—EGFR—ovarian cancer	2.91e-06	0.000228	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MAPK1—ovarian cancer	2.9e-06	0.000227	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—EGFR—ovarian cancer	2.9e-06	0.000227	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CAV1—ovarian cancer	2.89e-06	0.000227	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SLC5A5—ovarian cancer	2.88e-06	0.000226	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDKN1B—ovarian cancer	2.88e-06	0.000226	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—AKT1—ovarian cancer	2.85e-06	0.000224	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—MAPK1—ovarian cancer	2.85e-06	0.000224	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—EGFR—ovarian cancer	2.85e-06	0.000223	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CASP3—ovarian cancer	2.83e-06	0.000222	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ABCB1—ovarian cancer	2.82e-06	0.000222	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL2—ovarian cancer	2.82e-06	0.000222	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—IL6—ovarian cancer	2.81e-06	0.00022	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CD—ovarian cancer	2.81e-06	0.00022	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.8e-06	0.00022	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CB—ovarian cancer	2.79e-06	0.000219	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SLC2A1—ovarian cancer	2.79e-06	0.000219	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CB—ovarian cancer	2.79e-06	0.000219	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—MAPK1—ovarian cancer	2.78e-06	0.000219	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—EGFR—ovarian cancer	2.78e-06	0.000219	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—PIK3CA—ovarian cancer	2.78e-06	0.000218	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—YAP1—ovarian cancer	2.78e-06	0.000218	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—TYMS—ovarian cancer	2.77e-06	0.000218	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCND1—ovarian cancer	2.75e-06	0.000216	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—KRAS—ovarian cancer	2.75e-06	0.000216	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CD—ovarian cancer	2.75e-06	0.000216	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KRAS—ovarian cancer	2.74e-06	0.000215	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CAV1—ovarian cancer	2.73e-06	0.000214	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.73e-06	0.000214	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CTNNB1—ovarian cancer	2.72e-06	0.000214	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—PIK3CA—ovarian cancer	2.72e-06	0.000214	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—TYMS—ovarian cancer	2.71e-06	0.000212	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—KRAS—ovarian cancer	2.69e-06	0.000211	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CD—ovarian cancer	2.69e-06	0.000211	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MMP9—ovarian cancer	2.67e-06	0.00021	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP1B1—ovarian cancer	2.67e-06	0.00021	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—PIK3CA—ovarian cancer	2.66e-06	0.000209	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTEN—ovarian cancer	2.66e-06	0.000208	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CG—ovarian cancer	2.63e-06	0.000207	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—KRAS—ovarian cancer	2.63e-06	0.000206	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.61e-06	0.000205	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.6e-06	0.000204	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—AKT1—ovarian cancer	2.59e-06	0.000203	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—TYMS—ovarian cancer	2.55e-06	0.0002	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PIK3CA—ovarian cancer	2.53e-06	0.000198	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PIK3CA—ovarian cancer	2.51e-06	0.000197	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CG—ovarian cancer	2.49e-06	0.000195	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ERBB2—ovarian cancer	2.48e-06	0.000195	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PIK3CA—ovarian cancer	2.47e-06	0.000194	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CB—ovarian cancer	2.45e-06	0.000192	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MTOR—ovarian cancer	2.45e-06	0.000192	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—ovarian cancer	2.43e-06	0.000191	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ERBB2—ovarian cancer	2.43e-06	0.00019	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PIK3CA—ovarian cancer	2.42e-06	0.00019	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTEN—ovarian cancer	2.41e-06	0.000189	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTEN—ovarian cancer	2.41e-06	0.000189	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—ovarian cancer	2.4e-06	0.000188	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MTOR—ovarian cancer	2.39e-06	0.000188	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CB—ovarian cancer	2.39e-06	0.000188	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—STAT3—ovarian cancer	2.38e-06	0.000186	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ERBB2—ovarian cancer	2.37e-06	0.000186	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRAS—ovarian cancer	2.37e-06	0.000186	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	2.37e-06	0.000186	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.36e-06	0.000185	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CXCL8—ovarian cancer	2.35e-06	0.000185	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MTOR—ovarian cancer	2.34e-06	0.000184	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CB—ovarian cancer	2.34e-06	0.000184	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—HRAS—ovarian cancer	2.34e-06	0.000183	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HRAS—ovarian cancer	2.33e-06	0.000183	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CD—ovarian cancer	2.31e-06	0.000182	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CXCL8—ovarian cancer	2.3e-06	0.000181	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1B—ovarian cancer	2.3e-06	0.00018	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—HRAS—ovarian cancer	2.29e-06	0.000179	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT1—ovarian cancer	2.27e-06	0.000178	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK3—ovarian cancer	2.27e-06	0.000178	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—FASN—ovarian cancer	2.26e-06	0.000178	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CASP3—ovarian cancer	2.25e-06	0.000177	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CXCL8—ovarian cancer	2.25e-06	0.000177	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL2—ovarian cancer	2.25e-06	0.000176	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1B—ovarian cancer	2.25e-06	0.000176	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL6—ovarian cancer	2.24e-06	0.000176	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—HRAS—ovarian cancer	2.24e-06	0.000175	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CAV1—ovarian cancer	2.23e-06	0.000175	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL6—ovarian cancer	2.23e-06	0.000175	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.23e-06	0.000175	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT1—ovarian cancer	2.22e-06	0.000174	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MYC—ovarian cancer	2.21e-06	0.000173	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CASP3—ovarian cancer	2.2e-06	0.000173	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ABCB1—ovarian cancer	2.2e-06	0.000173	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL2—ovarian cancer	2.2e-06	0.000173	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1B—ovarian cancer	2.2e-06	0.000172	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCND1—ovarian cancer	2.19e-06	0.000172	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL6—ovarian cancer	2.19e-06	0.000172	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CD—ovarian cancer	2.19e-06	0.000172	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CAV1—ovarian cancer	2.18e-06	0.000171	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT1—ovarian cancer	2.17e-06	0.000171	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CTNNB1—ovarian cancer	2.17e-06	0.00017	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—TYMS—ovarian cancer	2.16e-06	0.00017	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK1—ovarian cancer	2.16e-06	0.000169	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EGFR—ovarian cancer	2.16e-06	0.000169	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CASP3—ovarian cancer	2.15e-06	0.000169	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL2—ovarian cancer	2.15e-06	0.000169	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.15e-06	0.000169	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCND1—ovarian cancer	2.14e-06	0.000168	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL6—ovarian cancer	2.14e-06	0.000168	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.13e-06	0.000168	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MMP9—ovarian cancer	2.13e-06	0.000167	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CTNNB1—ovarian cancer	2.12e-06	0.000167	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTEN—ovarian cancer	2.12e-06	0.000166	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCND1—ovarian cancer	2.1e-06	0.000165	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MMP9—ovarian cancer	2.08e-06	0.000163	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CTNNB1—ovarian cancer	2.08e-06	0.000163	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTEN—ovarian cancer	2.07e-06	0.000162	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT1—ovarian cancer	2.06e-06	0.000162	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.06e-06	0.000162	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CAV1—ovarian cancer	2.05e-06	0.000161	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT1—ovarian cancer	2.05e-06	0.000161	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KRAS—ovarian cancer	2.04e-06	0.00016	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MMP9—ovarian cancer	2.03e-06	0.00016	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.03e-06	0.00016	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTEN—ovarian cancer	2.02e-06	0.000159	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT1—ovarian cancer	2.02e-06	0.000158	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CB—ovarian cancer	2.02e-06	0.000158	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.99e-06	0.000156	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	1.97e-06	0.000155	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	1.91e-06	0.00015	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CB—ovarian cancer	1.91e-06	0.00015	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—STAT3—ovarian cancer	1.89e-06	0.000148	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRAS—ovarian cancer	1.89e-06	0.000148	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	1.87e-06	0.000147	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.87e-06	0.000147	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	1.87e-06	0.000147	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—STAT3—ovarian cancer	1.85e-06	0.000145	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRAS—ovarian cancer	1.85e-06	0.000145	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.83e-06	0.000144	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	1.83e-06	0.000143	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—ovarian cancer	1.81e-06	0.000142	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—STAT3—ovarian cancer	1.81e-06	0.000142	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	1.81e-06	0.000142	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRAS—ovarian cancer	1.8e-06	0.000142	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.79e-06	0.00014	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	1.77e-06	0.000139	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MYC—ovarian cancer	1.76e-06	0.000138	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.75e-06	0.000137	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTEN—ovarian cancer	1.74e-06	0.000137	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CAV1—ovarian cancer	1.74e-06	0.000137	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HRAS—ovarian cancer	1.73e-06	0.000136	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	1.73e-06	0.000136	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	1.72e-06	0.000135	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MYC—ovarian cancer	1.72e-06	0.000135	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EGFR—ovarian cancer	1.72e-06	0.000135	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CA—ovarian cancer	1.7e-06	0.000134	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CA—ovarian cancer	1.7e-06	0.000133	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.7e-06	0.000133	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	1.68e-06	0.000132	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EGFR—ovarian cancer	1.68e-06	0.000132	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MYC—ovarian cancer	1.68e-06	0.000132	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—TYMS—ovarian cancer	1.67e-06	0.000131	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.66e-06	0.000131	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL6—ovarian cancer	1.66e-06	0.00013	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTEN—ovarian cancer	1.65e-06	0.000129	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.65e-06	0.000129	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	1.64e-06	0.000129	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EGFR—ovarian cancer	1.64e-06	0.000129	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KRAS—ovarian cancer	1.62e-06	0.000127	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KRAS—ovarian cancer	1.59e-06	0.000125	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.59e-06	0.000124	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.56e-06	0.000122	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.55e-06	0.000122	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT1—ovarian cancer	1.53e-06	0.00012	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.52e-06	0.000119	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	1.49e-06	0.000117	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	1.46e-06	0.000115	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—ovarian cancer	1.44e-06	0.000113	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.43e-06	0.000113	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.43e-06	0.000112	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—ovarian cancer	1.41e-06	0.000111	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.39e-06	0.000109	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AKT1—ovarian cancer	1.39e-06	0.000109	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AKT1—ovarian cancer	1.39e-06	0.000109	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.38e-06	0.000108	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HRAS—ovarian cancer	1.38e-06	0.000108	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HRAS—ovarian cancer	1.35e-06	0.000106	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTEN—ovarian cancer	1.35e-06	0.000106	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CAV1—ovarian cancer	1.34e-06	0.000105	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL6—ovarian cancer	1.32e-06	0.000104	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.32e-06	0.000104	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTEN—ovarian cancer	1.31e-06	0.000103	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL6—ovarian cancer	1.29e-06	0.000101	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.26e-06	9.92e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTEN—ovarian cancer	1.24e-06	9.73e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.23e-06	9.65e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.22e-06	9.61e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT1—ovarian cancer	1.22e-06	9.57e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.21e-06	9.54e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT1—ovarian cancer	1.19e-06	9.36e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.17e-06	9.15e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CA—ovarian cancer	1.16e-06	9.12e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.08e-06	8.44e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTEN—ovarian cancer	1.05e-06	8.24e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKT1—ovarian cancer	1e-06	7.88e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CA—ovarian cancer	9.5e-07	7.46e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKT1—ovarian cancer	9.49e-07	7.45e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CB—ovarian cancer	9.38e-07	7.36e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CA—ovarian cancer	9.28e-07	7.28e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CA—ovarian cancer	8.74e-07	6.86e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTEN—ovarian cancer	8.1e-07	6.36e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKT1—ovarian cancer	7.76e-07	6.1e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKT1—ovarian cancer	7.58e-07	5.95e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CA—ovarian cancer	7.41e-07	5.81e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKT1—ovarian cancer	7.14e-07	5.61e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKT1—ovarian cancer	6.05e-07	4.75e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CA—ovarian cancer	5.72e-07	4.49e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKT1—ovarian cancer	4.67e-07	3.67e-05	CbGpPWpGaD
